<SEC-DOCUMENT>0000950170-25-099705.txt : 20250729
<SEC-HEADER>0000950170-25-099705.hdr.sgml : 20250729
<ACCEPTANCE-DATETIME>20250729165445
ACCESSION NUMBER:		0000950170-25-099705
CONFORMED SUBMISSION TYPE:	SCHEDULE 13D/A
PUBLIC DOCUMENT COUNT:		1
FILED AS OF DATE:		20250729
DATE AS OF CHANGE:		20250729

SUBJECT COMPANY:	

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Guardian Pharmacy Services, Inc.
		CENTRAL INDEX KEY:			0001802255
		STANDARD INDUSTRIAL CLASSIFICATION:	RETAIL-DRUG STORES AND PROPRIETARY STORES [5912]
		ORGANIZATION NAME:           	07 Trade & Services
		EIN:				200100834
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	005-94641
		FILM NUMBER:		251162506

	BUSINESS ADDRESS:	
		STREET 1:		300 GALLERIA PARKWAY SE
		STREET 2:		SUITE 800
		CITY:			ATLANTA
		STATE:			GA
		ZIP:			30339
		BUSINESS PHONE:		(404) 810-0089

	MAIL ADDRESS:	
		STREET 1:		300 GALLERIA PARKWAY SE
		STREET 2:		SUITE 800
		CITY:			ATLANTA
		STATE:			GA
		ZIP:			30339

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Guardian Pharmacy, LLC
		DATE OF NAME CHANGE:	20200204

FILED BY:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Bindley Capital Partners I, LLC
		CENTRAL INDEX KEY:			0002038820
		ORGANIZATION NAME:           	
		EIN:				352154985
		STATE OF INCORPORATION:			IN
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		SCHEDULE 13D/A

	BUSINESS ADDRESS:	
		STREET 1:		8909 PURDUE ROAD
		STREET 2:		#500
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46268
		BUSINESS PHONE:		(317) 704-4105

	MAIL ADDRESS:	
		STREET 1:		8909 PURDUE ROAD
		STREET 2:		#500
		CITY:			INDIANAPOLIS
		STATE:			IN
		ZIP:			46268
</SEC-HEADER>
<DOCUMENT>
<TYPE>SCHEDULE 13D/A
<SEQUENCE>1
<FILENAME>primary_doc.xml
<TEXT>
<XML>
<?xml version="1.0" encoding="UTF-8"?><edgarSubmission xmlns="http://www.sec.gov/edgar/schedule13D" xmlns:xsd="http://www.w3.org/2001/XMLSchema" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
  <headerData>
    <submissionType>SCHEDULE 13D/A</submissionType>
    <filerInfo>
      <filer>
        <filerCredentials>
          <cik>0002038820</cik>
          <ccc>XXXXXXXX</ccc>
        </filerCredentials>
      </filer>
      <liveTestFlag>LIVE</liveTestFlag>



    </filerInfo>
  </headerData>
  <formData>
    <coverPageHeader>
      <amendmentNo>2</amendmentNo>
      <securitiesClassTitle> Class A Common Stock, par value $0.001 per share</securitiesClassTitle>
      <dateOfEvent>07/29/2025</dateOfEvent>
      <previouslyFiledFlag>false</previouslyFiledFlag>
      <issuerInfo>
        <issuerCIK>0001802255</issuerCIK>
        <issuerCUSIP>40145W101</issuerCUSIP>
        <issuerName>Guardian Pharmacy Services, Inc.</issuerName>
        <address>
          <street1 xmlns="http://www.sec.gov/edgar/common">300 Galleria Parkway SE</street1>
          <street2 xmlns="http://www.sec.gov/edgar/common">Suite 800</street2>
          <city xmlns="http://www.sec.gov/edgar/common">Atlanta</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">GA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">30339</zipCode>
        </address>
      </issuerInfo>
      <authorizedPersons>
        <notificationInfo>
          <personName>Bindley Capital Partners I LLC</personName>
          <personPhoneNum>(317) 704-4162</personPhoneNum>
          <personAddress>
            <street1 xmlns="http://www.sec.gov/edgar/common">(Attn: William E. Bindley)</street1>
            <street2 xmlns="http://www.sec.gov/edgar/common">8909 Purdue Road, Suite 500</street2>
            <city xmlns="http://www.sec.gov/edgar/common">Indianapolis</city>
            <stateOrCountry xmlns="http://www.sec.gov/edgar/common">IN</stateOrCountry>
            <zipCode xmlns="http://www.sec.gov/edgar/common">46268</zipCode>
          </personAddress>
        </notificationInfo>
      </authorizedPersons>
    </coverPageHeader>
    <reportingPersons>
      <reportingPersonInfo>
        <reportingPersonCIK>0002038820</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Bindley Capital Partners I, LLC</reportingPersonName>
        <memberOfGroup>a</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>IN</citizenshipOrOrganization>
        <soleVotingPower>8039993</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>8039993</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
        <aggregateAmountOwned>8039993</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>22.2</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>Bindley Capital Partners I, LLC ("Bindley Capital") currently owns an aggregate of 1,939,817 shares of Class A common stock, par value $0.001 per share ("Class A common stock") and 18,300,526 shares of Class B common stock, par value $0.001 per share ("Class B common stock"), of Guardian Pharmacy Services, Inc. (the "Issuer"). Pursuant to the Issuer's Amended and Restated Certificate of Incorporation (the "Charter"), such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026.

The shares reported in Rows 7, 9 and 11 in the table above represent 1,939,817 outstanding shares of Class A common stock beneficially owned by Bindley Capital, and 6,100,176 shares of Class A common stock that will be issued to Bindley Capital on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025.

The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the Issuer's Quarterly Report on Form 10-Q filed with the SEC on May 12, 2025 (the "10-Q")), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.
</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0000903539</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>William E. Bindley</reportingPersonName>
        <memberOfGroup>a</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>0</soleVotingPower>
        <sharedVotingPower>8039993</sharedVotingPower>
        <soleDispositivePower>0</soleDispositivePower>
        <sharedDispositivePower>8039993</sharedDispositivePower>
        <aggregateAmountOwned>8039993</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>22.2</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>William E. Bindley shares voting and investment power with Thomas J. Salentine, Jr. over an aggregate of 1,939,817 shares of Class A common stock and 18,300,526 shares of Class B common stock currently owned by Bindley Capital by virtue of his position as member and officer of Bindley Capital Partners, LLC, the manager of Bindley Capital. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026.

The shares reported in Rows 8, 10 and 11 in the table above represent 1,939,817 outstanding shares of Class A common stock beneficially owned by Mr. Bindley, and 6,100,176 shares of Class A common stock that will be issued to Bindley Capital on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025.

The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.
</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0002037899</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Thomas J. Salentine, Jr.</reportingPersonName>
        <memberOfGroup>a</memberOfGroup>
        <fundType>OO</fundType>
        <fundType>PF</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>35714</soleVotingPower>
        <sharedVotingPower>8039993</sharedVotingPower>
        <soleDispositivePower>35714</soleDispositivePower>
        <sharedDispositivePower>8039993</sharedDispositivePower>
        <aggregateAmountOwned>8075707</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>22.3</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>Thomas J. Salentine, Jr. directly owns 35,714 shares of Class A common stock. Mr. Salentine, Jr. also shares voting and investment power with William E. Bindley over an aggregate of 1,939,817 shares of Class A common stock and 18,300,526 shares of Class B common stock currently owned by Bindley Capital by virtue of his position as member and officer of Bindley Capital Partners, LLC, the manager of Bindley Capital. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026.

The shares reported in Rows 7 and 9 in the table above represent 35,714 outstanding shares of Class A common stock directly owned by Mr. Salentine, Jr. The shares reported in Rows 8 and 10 represent 1,939,817 outstanding shares of Class A common stock beneficially owned by Mr. Salentine, Jr., and 6,100,176 shares of Class A common stock that will be issued to Bindley Capital on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The shares reported in Row 11 represent the aggregate amount of shares of Class A common stock beneficially owned by the Reporting Person.

The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.
</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0002038519</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Pharmacy Investors, LLC</reportingPersonName>
        <memberOfGroup>a</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>IN</citizenshipOrOrganization>
        <soleVotingPower>1863564</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>1863564</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
        <aggregateAmountOwned>1863564</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>5.1</percentOfClass>
        <typeOfReportingPerson>OO</typeOfReportingPerson>
        <commentContent>Pharmacy Investors, LLC ("Pharmacy Investors") currently owns an aggregate of 449,624 shares of Class A common stock and 4,241,818 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026.

The shares reported in Rows 7, 9 and 11 in the table above represent 449,624 outstanding shares of Class A common stock beneficially owned by Pharmacy Investors, and 1,413,940 shares of Class A common stock that will be issued to Pharmacy Investors on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025.

The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.
</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0002037898</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>John Ackerman</reportingPersonName>
        <memberOfGroup>a</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>1863564</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>1863564</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
        <aggregateAmountOwned>1863564</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>5.1</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>John Ackerman has voting and investment power over an aggregate of 449,624 shares of Class A common stock and 4,241,818 shares of Class B common stock currently owned by Pharmacy Investors by virtue of his position as Manager of Pharmacy Investors, LLC. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026.

The shares reported in Rows 7, 9 and 11 in the table above represent 449,624 outstanding shares of Class A common stock beneficially owned by Mr. Ackerman, and 1,413,940 shares of Class A common stock that will be issued to Pharmacy Investors on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025.

The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.
</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0001432819</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Cardinal Equity Fund, L.P.</reportingPersonName>
        <memberOfGroup>a</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>DE</citizenshipOrOrganization>
        <soleVotingPower>620851</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>620851</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
        <aggregateAmountOwned>620851</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>1.7</percentOfClass>
        <typeOfReportingPerson>PN</typeOfReportingPerson>
        <commentContent>Cardinal Equity Fund, L.P. ("Cardinal") currently owns an aggregate of 149,794 shares of Class A common stock and 1,413,171 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026.

The shares reported in Rows 7, 9 and 11 in the table above represent 149,794 outstanding shares of Class A common stock beneficially owned by Cardinal, and 471,057 shares of Class A common stock that will be issued to Cardinal on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. Investment and voting decisions for the shares held by Cardinal require unanimous consent of the investment committee of Cardinal Equity Partners, LLC, the general partner of Cardinal. The investment committee consists of John Ackerman, James L. Smeltzer, Peter J. Munson, Darrell E. Zink and Michael E. Smith. Therefore, no individual member of the investment committee is deemed to be the beneficial owner of the shares reported in this Schedule 13D.

The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.
</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0002037972</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>Fred P. Burke</reportingPersonName>
        <memberOfGroup>a</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>1711845</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>1711845</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
        <aggregateAmountOwned>1711845</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>4.7</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>Fred P. Burke currently owns an aggregate of 413,019 shares of Class A common stock and 3,896,477 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026.

The shares reported in Rows 7, 9 and 11 in the table above represent 413,019 outstanding shares of Class A common stock beneficially owned by Mr. Burke, and 1,298,826 shares of Class A common stock that will be issued to Mr. Burke on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025.

The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.
</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0002037977</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>David K. Morris</reportingPersonName>
        <memberOfGroup>a</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>845979</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>845979</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
        <aggregateAmountOwned>845979</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>2.3</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>David K. Morris currently owns an aggregate of 204,110 shares of Class A common stock and 1,925,608 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026.

The shares reported in Rows 7, 9 and 11 in the table above represent 204,110 outstanding shares of Class A common stock beneficially owned by Mr. Morris, and 641,869 shares of Class A common stock that will be issued to Mr. Morris on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025.

The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.
</commentContent>
      </reportingPersonInfo>
      <reportingPersonInfo>
        <reportingPersonCIK>0002038507</reportingPersonCIK>
        <reportingPersonNoCIK>N</reportingPersonNoCIK>
        <reportingPersonName>G. Kendall Forbes</reportingPersonName>
        <memberOfGroup>a</memberOfGroup>
        <fundType>OO</fundType>
        <legalProceedings>N</legalProceedings>
        <citizenshipOrOrganization>X1</citizenshipOrOrganization>
        <soleVotingPower>802091</soleVotingPower>
        <sharedVotingPower>0</sharedVotingPower>
        <soleDispositivePower>802091</soleDispositivePower>
        <sharedDispositivePower>0</sharedDispositivePower>
        <aggregateAmountOwned>802091</aggregateAmountOwned>
        <isAggregateExcludeShares>N</isAggregateExcludeShares>
        <percentOfClass>2.2</percentOfClass>
        <typeOfReportingPerson>IN</typeOfReportingPerson>
        <commentContent>G. Kendall Forbes currently owns an aggregate of 193,521 shares of Class A common stock and 1,825,710 shares of Class B common stock. Pursuant to the Charter, such shares of Class B common stock will automatically convert into shares of Class A common stock on a one-for-one basis in substantially equal tranches on each of September 27, 2025, March 28, 2026 and September 27, 2026. The shares reported in Rows 7, 9 and 11 in the table above represent 193,521 outstanding shares of Class A common stock beneficially owned by Mr. Forbes, and 608,570 shares of Class A common stock that will be issued to Mr. Forbes on September 27, 2025 upon the automatic conversion of an equal number of shares of Class B common stock on such date pursuant to the Charter. The Reporting Person is deemed to beneficially own such shares of Class A common stock pursuant to Rule 13d-3(d)(1)(i), commencing on July 29, 2025. The percentage reflected in Row 13 in the table above is calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q), and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.</commentContent>
      </reportingPersonInfo>
    </reportingPersons>
    <items1To7>
      <item1>
        <securityTitle>Class A Common Stock, par value $0.001 per share</securityTitle>
        <issuerName>Guardian Pharmacy Services, Inc.</issuerName>
        <issuerPrincipalAddress>
          <street1 xmlns="http://www.sec.gov/edgar/common">300 Galleria Parkway SE</street1>
          <street2 xmlns="http://www.sec.gov/edgar/common">Suite 800</street2>
          <city xmlns="http://www.sec.gov/edgar/common">Atlanta</city>
          <stateOrCountry xmlns="http://www.sec.gov/edgar/common">GA</stateOrCountry>
          <zipCode xmlns="http://www.sec.gov/edgar/common">30339</zipCode>
        </issuerPrincipalAddress>
        <commentText>EXPLANATORY NOTE: This Schedule 13D is intended to serve as Amendment No. 2 to the Statement on Schedule 13D ("Amendment No. 2") related to the shares of Class A common stock, par value $0.001 per share ("Class A common stock") of Guardian Pharmacy Services, Inc. (the "Issuer"), and amends the initial statement on Schedule 13D filed by the Reporting Persons (as defined below) on February 3, 2025, as amended by Amendment No. 1 thereto filed on May 29, 2025, and as further amended by this Amendment No. 2 (collectively, the "Schedule 13D"). Except as specifically provided herein, this Amendment No. 2 does not modify any information previously reported in the Schedule 13D. Capitalized terms used but not defined in this Amendment No. 2 shall have the same meanings herein as are ascribed to such terms in the Schedule 13D. This Amendment No. 2 is being jointly filed by Bindley Capital Partners I, LLC ("Bindley Capital"), William E. Bindley, Thomas J. Salentine, Jr., Pharmacy Investors, LLC ("Pharmacy Investors"), John Ackerman, Cardinal Equity Fund, L.P. ("Cardinal"), Fred P. Burke, David K. Morris and G. Kendall Forbes (each a "Reporting Person," and collectively, the "Reporting Persons").</commentText>
      </item1>
      <item3>
        <fundsSource>As of the date hereof, the Reporting Persons, collectively, beneficially own 13,920,037 shares of Class A common stock.</fundsSource>
      </item3>
      <item5>
        <percentageOfClassSecurities>As of the date hereof, the Reporting Persons, collectively, beneficially own 13,920,037 shares of Class A common stock, representing approximately 38.4% of the shares of Class A common stock, calculated based on 36,241,594 shares of Class A common stock outstanding, which consists of (i) 22,719,946 shares of Class A common stock outstanding as of May 1, 2025 (as disclosed in the 10-Q, and (ii) 13,521,648 shares of Class A common stock that will be issued upon the automatic conversion of an equal number of shares of Class B common stock on September 27, 2025.</percentageOfClassSecurities>
        <numberOfShares>The aggregate number and percentage of shares of Class A common stock beneficially owned by each Reporting Person and, for each Reporting Person, the number of shares of Class A common stock as to which there is sole power to vote or to direct the vote, shared power to vote or to direct the vote, sole power to dispose or to direct the disposition, or shared power to dispose or to direct the disposition are set forth on Rows 7 through 11 and Row 13 of the cover pages of this Schedule 13D and are incorporated herein by reference.</numberOfShares>
        <transactionDesc>Except as set forth in the Schedule 13D, no transactions in the shares of Class A common stock were effected by the Reporting Persons, or, to the knowledge of the Reporting Persons, any of the persons listed on Schedule A hereto in the 60 days preceding the date of the Schedule 13D.  </transactionDesc>
        <listOfShareholders>Except as described herein, to the knowledge of the Reporting Persons, no other person has the right to receive or the power to direct the receipt of dividends from, or the proceeds from the sale of, any shares of Class A common stock of the Issuer beneficially owned by the Reporting Persons as described in this Item 5.</listOfShareholders>
        <date5PercentOwnership>Not applicable.</date5PercentOwnership>
      </item5>
      <item7>
        <filedExhibits>Exhibit 99.1 Stockholders' Agreement, dated as of September 25, 2024, by and among Guardian Pharmacy Services, Inc., Bindley Capital Partners I, LLC, Pharmacy Investors, LLC, Cardinal Equity Fund LP, Fred Burke, David Morris and Kendall Forbes (incorporated by reference to Exhibit 4.1 of the Issuer's Current Report on Form 8-K filed with the Securities and Exchange Commission on September 30, 2024).

Exhibit 99.2 Joint Filing Agreement as required by Rule 13d-1(k)(1) under the Exchange Act (incorporated by reference to the Schedule 13D filed with the Securities and Exchange Commission on February 3, 2025).</filedExhibits>
      </item7>
    </items1To7>
    <signatureInfo>
      <signaturePerson>
        <signatureReportingPerson>Bindley Capital Partners I, LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Thomas J. Salentine, Jr.</signature>
          <title>Member</title>
          <date>07/29/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>William E. Bindley</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ William E. Bindley, individually</signature>
          <title>William E. Bindley, individually</title>
          <date>07/29/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Thomas J. Salentine, Jr.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Thomas J. Salentine, Jr., individually</signature>
          <title>Thomas J. Salentine, Jr., individually</title>
          <date>07/29/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Pharmacy Investors, LLC</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ John Ackerman</signature>
          <title>Managing Member</title>
          <date>07/29/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>John Ackerman</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ John Ackerman, individually</signature>
          <title>John Ackerman, individually</title>
          <date>07/29/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Cardinal Equity Fund, L.P.</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ John Ackerman, by Cardinal Equity Partners, LLC, its General Partner</signature>
          <title>Managing Member</title>
          <date>07/29/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>Fred P. Burke</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ Fred P. Burke, individually</signature>
          <title>Fred P. Burke, individually</title>
          <date>07/29/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>David K. Morris</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ David K. Morris, individually</signature>
          <title>David K. Morris, individually</title>
          <date>07/29/2025</date>
        </signatureDetails>
      </signaturePerson>
      <signaturePerson>
        <signatureReportingPerson>G. Kendall Forbes</signatureReportingPerson>
        <signatureDetails>
          <signature>/s/ G. Kendall Forbes, individually</signature>
          <title>G. Kendall Forbes, individually</title>
          <date>07/29/2025</date>
        </signatureDetails>
      </signaturePerson>
    </signatureInfo>
  </formData>
</edgarSubmission>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
